Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01923337 · ClinicalTrials.gov registry record · Phase 1
Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01923337 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 17 participants.
The verdict
NCT01923337, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of alisertib when given together with irinotecan hydrochloride in treating patients with advanced solid tumors or colorectal cancer. Irinotecan hydrochloride and alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG alisertib
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01923337
The ClinicalTrials.gov registry entry for NCT01923337 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which alisertib is the first listed.
NCT01923337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01923337 about?
NCT01923337 is a clinical study titled "Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer". This phase I trial studies the side effects and best dose of alisertib when given together with irinotecan hydrochloride in treating patients with advanced solid tumors or colorectal cancer. Irinotecan hydrochloride and alisertib may stop the growth of tumor cells by blocking some of the enzymes nee...
What is the current status of trial NCT01923337?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2013-08. Estimated completion is 2016-10-17.
What interventions are being tested in trial NCT01923337?
The interventions under investigation include: alisertib (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01923337?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.